celecoxib has been researched along with Degenerative Diseases, Central Nervous System in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Swarbrick, ME | 1 |
| Beswick, PJ | 1 |
| Gleave, RJ | 1 |
| Green, RH | 1 |
| Bingham, S | 1 |
| Bountra, C | 1 |
| Carter, MC | 1 |
| Chambers, LJ | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Collins, SD | 1 |
| Corfield, JA | 1 |
| Hartley, CD | 1 |
| Kleanthous, S | 1 |
| Lambeth, PF | 1 |
| Lucas, FS | 1 |
| Mathews, N | 1 |
| Naylor, A | 1 |
| Page, LW | 1 |
| Payne, JJ | 1 |
| Pegg, NA | 1 |
| Price, HS | 1 |
| Skidmore, J | 1 |
| Stevens, AJ | 1 |
| Stocker, R | 1 |
| Stratton, SC | 1 |
| Stuart, AJ | 1 |
| Wiseman, JO | 1 |
| Salomon-Zimri, S | 1 |
| Pushett, A | 1 |
| Russek-Blum, N | 1 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 1 |
| Drory, VE | 1 |
| Al Kury, LT | 1 |
| Zeb, A | 1 |
| Abidin, ZU | 1 |
| Irshad, N | 1 |
| Malik, I | 1 |
| Alvi, AM | 1 |
| Khalil, AAK | 1 |
| Ahmad, S | 1 |
| Faheem, M | 1 |
| Khan, AU | 1 |
| Shah, FA | 1 |
| Li, S | 1 |
| Gholizadeh, E | 1 |
| Karbalaei, R | 1 |
| Khaleghian, A | 1 |
| Salimi, M | 1 |
| Gilany, K | 1 |
| Soliymani, R | 1 |
| Tanoli, Z | 1 |
| Rezadoost, H | 1 |
| Baumann, M | 1 |
| Jafari, M | 1 |
| Tang, J | 1 |
| Villa, V | 1 |
| Thellung, S | 1 |
| Bajetto, A | 1 |
| Gatta, E | 1 |
| Robello, M | 1 |
| Novelli, F | 1 |
| Tasso, B | 1 |
| Tonelli, M | 1 |
| Florio, T | 1 |
| Borre, Y | 1 |
| Lemstra, S | 1 |
| Westphal, KG | 1 |
| Morgan, ME | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Casolini, P | 1 |
| Catalani, A | 1 |
| Zuena, AR | 1 |
| Angelucci, L | 1 |
| Sairam, K | 1 |
| Saravanan, KS | 1 |
| Banerjee, R | 1 |
| Mohanakumar, KP | 1 |
| Gobbo, OL | 1 |
| O'Mara, SM | 1 |
1 trial available for celecoxib and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
8 other studies available for celecoxib and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2009 |
Neuroprotective effects of melatonin and celecoxib against ethanol-induced neurodegeneration: a computational and pharmacological approach.
Topics: Animals; Celecoxib; Computational Biology; Disease Models, Animal; Ethanol; Injections, Intraperiton | 2019 |
Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromatography, Liquid; Gene Expression | 2021 |
Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
Topics: Animals; Astrocytes; Celecoxib; Cell Line; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Infla | 2016 |
Celecoxib delays cognitive decline in an animal model of neurodegeneration.
Topics: Analysis of Variance; Animals; Celecoxib; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokine | 2012 |
Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.
Topics: Aging; Animals; Celecoxib; Cognition Disorders; Corticosterone; Cyclooxygenase 2; Cyclooxygenase 2 I | 2002 |
Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Corpus Str | 2003 |
Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor celecoxib markedly enhances functional recovery from kainic acid-induced neurodegeneration.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Celecoxib; Cell | 2004 |